Back To Search Results

Efavirenz

Editor: Charles V. Preuss Updated: 2/28/2024 3:59:44 AM

Indications

Efavirenz is an FDA-approved medication used for the treatment and prevention of HIV-1 infection. The drug is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Like most other NNRTI agents, it is commonly combined with other agents with different mechanisms of action in antiretroviral therapy (ART) regimens. However, efavirenz has recently fallen out of favor due to its unfavorable adverse effect profile.[1]

FDA-Approved Indications

  • HIV infection in adults
  • HIV infection in children aged 3 and older

Off-Label Uses

Efavirenz is sometimes used off-label for HIV infection prevention (occupational exposure, perinatal transmission).

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

Efavirenz is a non-nucleoside reverse transcriptase inhibitor drug (NNRTI); it binds to a non-catalytic site of the HIV reverse transcription enzyme, inhibiting its activity and resulting in DNA chain termination. This action blocks DNA polymerase activities, including HIV replication. Though therapeutic drug concentration monitoring is not necessary for efavirenz, it is important to achieve adequate serum concentrations. Low concentrations are associated with virologic failure, while higher concentrations are associated with increased adverse effects such as sleep disorders.[2] Efavirenz is available in combination with other antiviral medications.[3]

The administration of efavirenz with food has been shown to increase serum concentrations and the incidence of adverse effects. For this reason, patients should not take efavirenz with food.[4] Peak concentrations are reached within 5 hours following a single oral dose, with steady-state plasma concentrations achieved in 6 to 7 days. The half-life of efavirenz is roughly 45 hours, making once-daily dosing suitable. Efavirenz is highly protein-bound to human plasma proteins, predominantly albumin. Efavirenz converts to inactive hydroxylated metabolites by the action of the CYP3A4 enzyme.[5] 

Pharmacokinetics

Absorption: Efavirenz is absorbed well following oral administration, and peak concentrations are achieved 5 hours after dosing. Steady-state plasma concentrations are attained in 6 to 10 days.

Distribution: The volume of distribution for efavirenz is approximately 252 L.

Metabolism: Efavirenz metabolism primarily occurs via the hepatic CYP450 enzyme system, specifically CYP2AB, into hydroxylated metabolites with subsequent glucuronidation. The drug is a primary CYP3A4 substrate.

Elimination: Excretion of efavirenz is via the feces (16% to 61%) and urine (14% to 34%), with <1% unchanged. The drug's half-life is between 40 and 55 hours.[2]

Administration

Available Dosage Forms and Strengths

Efavirenz is available as an oral capsule or tablet by prescription only. Efavirenz is also available as a component of 2 combination formulations: efavirenz, emtricitabine, and tenofovir disoproxil fumarate; and efavirenz, lamivudine, and tenofovir disoproxil fumarate. The capsules are available in 50 mg and 200 mg strengths, while the tablets are 600 mg. The recommended adult dose is 600 mg/d, but some data show that 400 mg/d yields equivalent outcomes with fewer adverse effects.[6] Patients should not cut, crush, or chew the tablets.

The administration of efavirenz with food has been shown to increase serum concentrations and the incidence of adverse effects.[4] Efavirenz dosing should be on an empty stomach, as increased efavirenz serum concentrations occur when taken with food. Increased serum concentrations can lead to increased adverse effects.[7] Efavirenz is often given in combination therapy with tenofovir and either emtricitabine or lamivudine.

Adult Dosing

HIV Infection

The dose is 600 mg orally, administered at bedtime.

HIV Prophylaxis (Off-Label)

Off-label HIV prophylaxis should be initiated as soon as possible after exposure but only following expert consultation. The optimal prophylaxis duration has not been established via empirical data and may differ according to institutional protocols.

Pediatric Dosing

The following dosing recommendations for efavirenz therapy for patients aged 3 and older are outlined below. These dosages are taken orally at bedtime.

  • Patients 10 to 14.9 kg: 200 mg
  • Patients 15 to 19.9 kg: 250 mg
  • Patients 20 to 24.9 kg: 300 mg
  • Patients 25 to 32.4 kg: 350 mg
  • Patients 32.5 to 39.49 kg: 400 mg
  • Patients >40 kg: 600 mg

Specific Patient Populations

Hepatic impairment: No dose adjustments are necessary for mild hepatic impairment (Child-Pugh class A), but caution is advisable. Efavirenz is not recommended in patients with moderate to severe impairment (Child-Pugh class B or C). 

Renal impairment: The manufacturer recommends no renal dose adjustments. No data is available for patients on dialysis.

Pregnancy considerations: Efavirenz may be used during pregnancy if necessary, but there is a potential risk for fetal harm in the first trimester based on limited human data (pregnancy category D). Clinicians should obtain a negative pregnancy test before initiating treatment, and patients should avoid pregnancy with forms of contraception, with 1 of those being a barrier method, during treatment and for 12 weeks following treatment cessation in female patients. Patients should be enrolled in the Antiretroviral Pregnancy Registry.[8]

Breastfeeding considerations: Females using efavirenz should avoid breastfeeding, as there is a risk of postnatal HIV transmission despite ongoing HIV treatment. Research has not shown whether efavirenz affects maternal milk production.

Pediatric patients: See pediatric dosing above. Not approved for use in children younger than age 3.

Older patients: Limited data regarding antiretroviral drugs and older patients is available. As HIV patients live longer, more studies are needed to determine the effects of age on antiretroviral therapy.[9]

Adverse Effects

As a drug class, NNRTIs are commonly associated with central nervous system (CNS) effects. These effects include impaired concentration, vivid or abnormal dreams, insomnia, suicidal ideation, nausea, and vomiting.[10] Patients who experience these adverse effects are more likely to be non-adherent and discontinue their antiretroviral therapy, leading to anti-virologic therapeutic failure.[11] These symptoms typically arise in the first few days of treatment and decline within a few weeks of continued therapy.[5] Lipodystrophy is also a common adverse effect of all NNRTIs and may occur during treatment with efavirenz.[5] Other commonly encountered adverse events include rash, elevated AST or ALT, decreased neutrophils, hyperglycemia, and hyperlipidemia.

Resistance to NNRTIs, including efavirenz, occurs through reverse transcriptase gene mutations in the viral genome. Drug resistance can develop quickly when nonnucleoside reverse transcriptase inhibitors are used as monotherapy for HIV-1 infection. NNRTI-naïve patients with previous nucleoside analog reverse transcriptase inhibitor (NRTI) exposure with isolates with resistance mutations and phenotypic resistance to NRTIs appear more likely to have hypersusceptibility to the NNRTI class of drugs.[12]

Drug-Drug Interactions

Like most NNRTIs, efavirenz correlates with many drug interactions due to the phase I cytochrome P450 (CYP) enzymes. Efavirenz is an in vitro inhibitor of CYP3A4, CYP2C9, and CYP2C19. The drug is a substrate, inducer, and inhibitor of CYP3A4.[13] Medications that undergo metabolism through CYP2B6, 3A4, 2C9, and 2C19, and those that undergo glucuronidation, may also interact with efavirenz. Drugs that are contraindicated with efavirenz due to interactions include dasabuvir, grazoprevir, ritonavir, and voriconazole.[14]

Contraindications

The use of efavirenz is contraindicated in patients with previously documented hypersensitivity to efavirenz and patients concurrently receiving elbasvir/grazoprevir due to a CYP3A4 interaction. Efavirenz should not be used in patients with Child-Pugh impairment class B or C. Efavirenz acts as a CYP3A4 inducer, in this case, by decreasing the serum concentrations of grazoprevir.[15] Efavirenz is also contraindicated in pregnant women in the first trimester due to reports of neural tube defects, and females should avoid breastfeeding. Caution is advised in patients who are poor CYP2B6 metabolizers.[16]

Monitoring

Adolescent and adult patients should have LFTs measured at baseline, then 2 to 8 weeks following therapy initiation or with any change, then every 3 to 6 months. Lipid profiles are also recommended at baseline and every 6 to 12 months after that. Female patients of childbearing age should have a baseline pregnancy test. Pediatric patients should have baseline LFTs with a 3 to 4-month follow-up and a baseline lipid profile with a 6 to 12-month follow-up.[17] As a predominant adverse effect of efavirenz, psychiatric effects require monitoring in all patients. If these symptoms occur, the prescriber can attempt dose adjustments before changing medications. 

Toxicity

The toxicity of this drug is generally relative to serum concentrations. Overdose is uncommon, and life-threatening sequelae from acute overdose are rare. There is no antidote available for efavirenz overdose. Short-term toxicity is usually transient and does not require treatment interruption.[18]

Enhancing Healthcare Team Outcomes

Treatment with efavirenz can significantly improve the quality of life of patients infected with HIV, but its efficacy heavily relies on patient adherence. The neurologic adverse effects associated with efavirenz cause some patients to discontinue therapy. An interprofessional team of healthcare providers must become actively involved in caring for their HIV-positive patients. Key members of the team include pharmacists, physicians, advanced practice practitioners, nurses, and social workers. Obstacles to successful ART include a lack of social support and the financial burden of therapy. Healthcare providers must provide counsel regarding methods of coping with these adverse effects and promote medication adherence. Identifying appropriate opportunities for members of each discipline to provide care and encouragement is crucial to successful ART.[19]

There are several recommendations for healthcare providers to assist in increasing successful outcomes in patients diagnosed with HIV on ART.[20] These recommendations include the following:

  • Monitoring of successful entry into HIV care is recommended for individuals diagnosed with HIV. Nursing staff can play a significant role in this function and report their findings to the clinical team. Entry into care, defined as a visit with an HIV care provider, has demonstrated correlations with improved survival. 
  • Providers should obtain self-reported adherence routinely. Healthcare providers should ask patients about their appointment adherence. Nursing staff can play a significant role here in assessing pharmacotherapy adherence.
  • Pharmacy refill data is recommended for adherence monitoring if medication refills are not automatically sent to patients. Pharmacy refill data can help to confirm self-reported adherence. If the pharmacist notices irregular refill activity, they should respond immediately, contacting both the patient and the prescriber.
  • If regimens have equivalent efficacy, switching treatment-experienced patients receiving complex or poorly tolerated regimens to simpler once-daily regimens is recommended. A higher tablet/capsule burden is associated with lower adherence. Discussing the patient's tablet/capsule burden can identify an opportunity to improve compliance. The pharmacist can advise on newer combination formulations that decrease tablet/capsule burden.
  • Individual one-on-one ART education is recommended. Counseling, skills-building, and education increase adherence rates, which are crucial to therapeutic success.
  • Interprofessional education and counseling intervention approaches are recommended. Interprofessional teams can provide education regarding multiple factors that affect adherence.
  • Case management is necessary to minimize the number of adherence barriers in people experiencing homelessness. Assistance in acquiring mental health and substance abuse treatment and housing accommodations can significantly improve outcomes.

In summary, efavirenz therapy requires an interprofessional team approach, including all interprofessional healthcare team members collaborating across disciplines and engaging in open communication to achieve optimal patient outcomes.

References


[1]

Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. Journal of acquired immune deficiency syndromes (1999). 2018 Jan 1:77(1):102-109. doi: 10.1097/QAI.0000000000001562. Epub     [PubMed PMID: 28991888]


[2]

McDonagh EM, Lau JL, Alvarellos ML, Altman RB, Klein TE. PharmGKB summary: Efavirenz pathway, pharmacokinetics. Pharmacogenetics and genomics. 2015 Jul:25(7):363-76. doi: 10.1097/FPC.0000000000000145. Epub     [PubMed PMID: 25966836]


[3]

Desta Z, Gammal RS, Gong L, Whirl-Carrillo M, Gaur AH, Sukasem C, Hockings J, Myers A, Swart M, Tyndale RF, Masimirembwa C, Iwuchukwu OF, Chirwa S, Lennox J, Gaedigk A, Klein TE, Haas DW. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clinical pharmacology and therapeutics. 2019 Oct:106(4):726-733. doi: 10.1002/cpt.1477. Epub 2019 Jul 5     [PubMed PMID: 31006110]


[4]

Robarge JD, Metzger IF, Lu J, Thong N, Skaar TC, Desta Z, Bies RR. Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. Antimicrobial agents and chemotherapy. 2017 Jan:61(1):. doi: 10.1128/AAC.01813-16. Epub 2016 Dec 27     [PubMed PMID: 27799204]


[5]

Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. The Journal of antimicrobial chemotherapy. 2009 Nov:64(5):910-28. doi: 10.1093/jac/dkp334. Epub 2009 Sep 18     [PubMed PMID: 19767318]


[6]

ENCORE1 Study Group, Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, Mohapi L, Crabtree-Ramirez B, Jessen H, Kumar S, Winston A, Lee MP, Belloso W, Cooper DA, Emery S. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. The Lancet. Infectious diseases. 2015 Jul:15(7):793-802. doi: 10.1016/S1473-3099(15)70060-5. Epub 2015 Apr 12     [PubMed PMID: 25877963]

Level 1 (high-level) evidence

[7]

Homkham N, Cressey TR, Bouazza N, Ingsrisawang L, Techakunakorn P, Mekmullica J, Borkird T, Puangsombat A, Na-Rajsima S, Treluyer JM, Urien S, Jourdain G. Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children. PloS one. 2019:14(5):e0216868. doi: 10.1371/journal.pone.0216868. Epub 2019 May 16     [PubMed PMID: 31095608]


[8]

Portwood C, Sexton H, Kumarendran M, Brandon Z, Johnson B, Kirtley S, Hemelaar J. Perinatal outcomes associated with combination antiretroviral therapy compared with monotherapy. AIDS (London, England). 2023 Mar 1:37(3):489-501. doi: 10.1097/QAD.0000000000003432. Epub 2022 Nov 11     [PubMed PMID: 36695359]


[9]

Stader F, Courlet P, Kinvig H, Battegay M, Decosterd LA, Penny MA, Siccardi M, Marzolini C. Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. British journal of clinical pharmacology. 2021 Feb:87(2):458-470. doi: 10.1111/bcp.14402. Epub 2020 Jun 14     [PubMed PMID: 32470203]


[10]

Apostolova N, Blas-Garcia A, Galindo MJ, Esplugues JV. Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects. European journal of pharmacology. 2017 Oct 5:812():163-173. doi: 10.1016/j.ejphar.2017.07.016. Epub 2017 Jul 8     [PubMed PMID: 28690189]


[11]

Kim MJ, Kim SW, Chang HH, Kim Y, Jin S, Jung H, Park JH, Kim S, Lee JM. Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching. Infection & chemotherapy. 2015 Dec:47(4):231-8. doi: 10.3947/ic.2015.47.4.231. Epub 2015 Dec 30     [PubMed PMID: 26788406]


[12]

Hinay AA Jr, Kanai K, Tsuneki-Tokunaga A, Komatsu M, Telan EO, Kageyama S. In Vitro Susceptibility of HIV Isolates with High Growth Capability to Antiretroviral Drugs. International journal of molecular sciences. 2022 Dec 6:23(23):. doi: 10.3390/ijms232315380. Epub 2022 Dec 6     [PubMed PMID: 36499705]


[13]

Xu C, Desta Z. In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug metabolism and pharmacokinetics. 2013:28(4):362-71     [PubMed PMID: 23385314]


[14]

Gausi K, Wiesner L, Norman J, Wallis CL, Onyango-Makumbi C, Chipato T, Haas DW, Browning R, Chakhtoura N, Montepiedra G, Aaron L, McCarthy K, Bradford S, Vhembo T, Stranix-Chibanda L, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Nevrekhar N, Rouzier V, Kabugho E, Mutambanengwe M, Chanaiwa V, Nyati M, Mhembere T, Tongprasert F, Hesseling A, Shin K, Zimmer B, Costello D, Jean-Philippe P, Sterling TR, Theron G, Weinberg A, Gupta A, Denti P, IMPAACT P1078 (TB APPRISE) Study Group Team. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Clinical pharmacology and therapeutics. 2021 Apr:109(4):1034-1044. doi: 10.1002/cpt.2044. Epub 2020 Oct 16     [PubMed PMID: 32909316]


[15]

Rice DP Jr, Faragon JJ, Banks S, Chirch LM. HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals. Journal of clinical and translational hepatology. 2016 Sep 28:4(3):234-240     [PubMed PMID: 27777891]


[16]

Ford GR, Niehaus A, Joubert F, Pepper MS. Pharmacogenetics of CYP2A6, CYP2B6, and UGT2B7 in the Context of HIV Treatments in African Populations. Journal of personalized medicine. 2022 Dec 5:12(12):. doi: 10.3390/jpm12122013. Epub 2022 Dec 5     [PubMed PMID: 36556234]


[17]

Khemla S, Meesing A, Sribenjalux W, Chetchotisakd P. Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir. Drug target insights. 2023 Jan-Dec:17():45-53. doi: 10.33393/dti.2023.2529. Epub 2023 Apr 28     [PubMed PMID: 37153647]


[18]

Nazziwa R, Sekadde M, Kanyike F, Wobudeya E, Nabukeera-Barungi N. Efavirenz poisoning in a 12 year old HIV negative African boy. The Pan African medical journal. 2012:12():86     [PubMed PMID: 23077707]

Level 3 (low-level) evidence

[19]

Chendi BH, Okomo Assoumou MC, Jacobs GB, Yekwa EL, Lyonga E, Mesembe M, Eyoh A, Ikomey GM. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study. BMC infectious diseases. 2019 Feb 26:19(1):194. doi: 10.1186/s12879-019-3824-7. Epub 2019 Feb 26     [PubMed PMID: 30808298]


[20]

Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, Orrell C, Altice FL, Bangsberg DR, Bartlett JG, Beckwith CG, Dowshen N, Gordon CM, Horn T, Kumar P, Scott JD, Stirratt MJ, Remien RH, Simoni JM, Nachega JB. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Annals of internal medicine. 2012 Jun 5:156(11):817-33, W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291, W-292, W-293, W-294. doi: 10.7326/0003-4819-156-11-201206050-00419. Epub 2012 Mar 5     [PubMed PMID: 22393036]